The BCG Vaccine is a vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.
During a meeting in Lisbon, the partners of the BuruliVac research consortium found the project to be running smoothly, and getting closer to a vaccine against Buruli ulcer, a disfiguring and mutilating disease that causes a lot of suffering and now is difficult to treat. Several vaccine candidates work well in mice and are ready for further testing on blood of patients; one is ready for testing in mice.
Emergent BioSolutions Inc. today announced that it has received a multi-year grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to advance the development of MVA85A, a candidate vaccine against tuberculosis.
On 21 February Bill Gates met with Dr. Carlos Martin of the University of Zaragoza and members of his team in Madrid, Spain. The scientists are working on the development of MTBVAC, a new vaccine against tuberculosis (TB). Gates showed great interest in the scientific background of MTBVAC, the most advanced vaccine based on attenuation of Mycobacterium tuberculosis.
The incidence of tuberculosis (TB) in the U.S. is reported as being on the decrease, however untreated infected people act as a reservoir for disease. Any pool of the world's population harboring this disease gives cause for concern, especially since the BCG vaccine is only 70-80% effective at best. New research published in BioMed Central's open access journal BMC Public Health, shows that in 2009 the number of cases of TB reported across America was much lower than that recorded in previous years.
Researchers at Albert Einstein College of Medicine of Yeshiva University report in the September 4 online edition of Nature Medicine that they have developed a tuberculosis (TB) vaccine candidate that proved both potent and safe in animal studies.
Scientists have found a potential new mechanism to stimulate the body's own ability to fight cancer using Baculillus Calmette-Guerin (BCG) - the germ commonly used to inoculate against tuberculosis.
Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a Phase IIb proof-of-concept efficacy trial of a new investigational tuberculosis (TB) vaccine that involves people living with the human immunodeficiency virus.
New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.
About two years ago, Dr. Philippe Gros, a McGill University professor in the Department of Biochemistry and a Principal Investigator in thd McGill Life Sciences Complex, described a mouse mutant that was immunodeficient and hypersensitive to the Bacille Calmette-Gu-rin (BCG) vaccine and to tuberculosis (TB).
In recognition of World Tuberculosis Day on Thursday, the Financial Times published a series of stories on TB worldwide.
A WHO report released Wednesday says countries with the highest drug-resistant tuberculosis burdens are making progress in addressing the disease, "but despite the recent scale up in efforts, the world needs to do much more to get care to all [multi-drug resistant] patients who need it," WHO Director-General Margaret Chan said, Times LIVE reports.
Tuberculosis continues to pose a major global health threat. Someone in the world is newly infected with TB bacteria every second. Every year, more than 9 million people develop active TB and it claims about 2 million lives.
Scientists have discovered a protein secreted by tuberculosis bacteria that could be a promising new vaccine candidate, they report today in Proceedings of the National Academy of Sciences. The protein could also be used to improve diagnosis of TB.
Emergent BioSolutions Inc. announced that a joint delegation of Members of the European Parliament and representatives from the Oxford-Emergent Tuberculosis Consortium today visited the trial site where MVA85A, the world's most clinically advanced tuberculosis vaccine candidate in development, is being studied in a Phase IIb infant efficacy clinical trial.
Nele Festjens and Nico Callewaert of VIB and Ghent University have improved the efficacy of the vaccine for tuberculosis. The new vaccine affords - as already proven in mice - better protection against the disease. The development of a new tuberculosis vaccine is a priority in the fight against the disease which claims the lives of 1.7 million people each year. The current vaccine provides only partial protection.
A new discovery may explain why a tuberculosis vaccine is not as effective for some people as anticipated, and potentially explains why other vaccines do not work as well for some as they do for others.
The Aeras Global TB Vaccine Foundation is pleased to announce receipt of a grant from the United States Food and Drug Administration (FDA) to develop new biological and immunological biomarkers for TB vaccine development. The FDA grant, which supports the coordination of a multi-investigator project with researchers from the United States, the United Kingdom and South Africa, will provide $362,102 in the first year of funding.
At an international gathering of TB vaccine researchers in Tallinn today, the Aeras Global TB Vaccine Foundation announced it will initiate a clinical trial of an investigational live recombinant tuberculosis vaccine to be led by researchers at Saint Louis University in St. Louis, Missouri, USA. The announcement was made at the Second Global Forum on TB Vaccine Development.
Dutch biopharmaceutical company Crucell N.V. and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial in infants of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35.
A European-Asian collaboration of scientists, notably including CNRS, the Institut Pasteur in Paris, the Institut Pasteur Korea in Seoul (IP Korea/Equipe Avenir Inserm and the Université de Toulouse have identified ten virulence genes of the tubercle bacillus. The inactivation of these genes lessens the pathogenic effects of the bacillus.